What Every Pediatric Surgeon Should Know About Common Systemic Therapies for the Treatment of Renal Tumors in Children and Adolescents
Alicia D. Menchaca(Nationwide Children's Hospital), Jennifer H. Aldrink(Nationwide Children's Hospital), Meera Kotagal(Cincinnati Children's Hospital Medical Center), Elisabeth T. Tracy(University of North Carolina at Chapel Hill), Nicholas G. Cost(University of Colorado Denver), Richard D. Glick(Cohen Children's Medical Center), Andrew J. Murphy(St. Jude Children's Research Hospital), Shachi Srivatsa(Nationwide Children's Hospital), Marcus M. Malek(Children's Hospital of Pittsburgh), Elizabeth Fialkowski(Oregon Health & Science University), Rodrigo Romao(Izaak Walton Killam Health Centre), Kathleen Kieran(Seattle Children's Hospital), A Bazan Soto(Duke University), Amy E. Armstrong(Washington University in St. Louis)
Cited by 0
Related Papers
Perioperative Hyperglycemia and Risk of Adverse Events Among Patients With and Without Diabetes
|Annals of Surgery|2014|436
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)
|Neuro-Oncology|2022|136
Noninvasive Diagnosis of Infection Using Plasma Next-Generation Sequencing: A Single-Center Experience
|Open Forum Infectious Diseases|2019|131
Cell‐free DNA next‐generation sequencing successfully detects infectious pathogens in pediatric oncology and hematopoietic stem cell transplant patients at risk for invasive fungal disease
|Pediatric Blood & Cancer|2019|109
Pediatric injury patterns by year of age
|Journal of Pediatric Surgery|2013|106